Workflow
医疗器械及解决方案
icon
Search documents
向“质”而行、回报加码!深市核心公司让“双提升”理念落地生根丨深市“质量回报双提升”系列报道
证券时报· 2025-12-29 11:19
深市核心公司让"双提升"理念落地生根。 为推动上市公司持续优化经营、规范治理和回报投资者,助力信心提振、资本市场稳定和经济高质量发展,2024年2月1日,深交所启动"质 量回报双提升(简称'双提升')"专项行动。 数据显示,截至2025年11月底,471家深市白马股、权重股、龙头股公司踊跃响应,发布"双提升"行动方案,围绕增强主业意识、提高创新 发展能力、提升投资者回报水平等方面提出务实举措,同时拿出实招、硬招,用实际行动积极践行"双提升"理念,展现了"重质量、重回 报"鲜明特征,为资本市场稳定发展注入强劲动力,也让高质量发展理念在市场中落地生根。 聚焦主业强创新 筑牢发展"压舱石" 据统计,2022年至2024年,471家公司年度分红金额复合增长率达10.0%,分红水平稳步迈上新台阶。2024年度,433家公司实施现金分 红,合计分红金额3244.7亿元,占当年净利润比例高达43.6%。响应新"国九条""一年多次分红"的号召,2024年、2025年分别有141家、 163家公司实施中期分红,378家企业实现连续三年分红,让股东回报更具持续性与可预期性。 回购与增持同步发力,向市场传递积极信号。中伟股份堪称回 ...
平安证券晨会纪要-20250430
Ping An Securities· 2025-04-30 00:32
Key Insights - The report highlights the growth in the active bond fund sector, with a total of 3,263 funds and a total scale of 7.90 trillion yuan, reflecting a 1.0% increase quarter-on-quarter [7][8] - The performance of active bond funds showed mixed results, with short-term pure bond funds performing well due to rising government bond yields, while mixed secondary bond funds saw increased volatility [7][8] - The report indicates a shift in asset allocation within bond funds, with a decrease in bond positions and an increase in equity positions, particularly in sectors like non-ferrous metals and pharmaceuticals [8] Group 1: Active Bond Fund Overview - As of the end of Q1 2025, the number of active bond funds increased by 0.8% compared to the previous quarter, while the total fund scale rose by 1.0% [7] - In Q1 2025, 43 new active bond funds were issued, totaling 783.7 billion yuan, which is a 16.7% decrease from the previous quarter [7] - The issuance of medium to long-term pure bond funds decreased by 31.5%, while mixed secondary bond funds saw a 65.1% increase in issuance [7] Group 2: Company-Specific Insights - For Mindray Medical (300760.SZ), the company reported a revenue of 36.726 billion yuan in 2024, a year-on-year increase of 5.14%, with a net profit of 11.668 billion yuan, up 0.74% [9][10] - The company’s international business grew by 21.28%, accounting for approximately 45% of total revenue, indicating a strong international expansion strategy [11] - The report anticipates a recovery in domestic business by Q3 2025, despite a significant year-on-year decline in Q1 2025 [11] Group 3: Industry Trends - The report on Haibo Technology (688411.SH) indicates a revenue of 8.270 billion yuan in 2024, a growth of 18.44%, with a focus on energy storage systems [14][15] - The company’s energy storage product output and sales saw significant increases, with a 35.40% rise in production and a 90.19% increase in sales [15] - The report emphasizes the company’s leading position in the domestic energy storage market and its successful international partnerships [17] Group 4: Financial Performance - For Sanmei Co., Ltd. (603379.SH), the company achieved a revenue of 4.040 billion yuan in 2024, a 21.17% increase, with a net profit growth of 178.40% [24][25] - The report highlights the impact of rising refrigerant prices and strong demand from the home appliance and automotive sectors on the company’s financial performance [25][26] - The company is expected to maintain strong performance due to favorable supply-demand dynamics in the refrigerant market [28] Group 5: Future Outlook - The report suggests that the domestic medical device market, particularly for Mindray Medical, is poised for recovery, with expectations of improved performance in 2025 [11][12] - Haibo Technology is projected to continue its growth trajectory, supported by its strong market position and international expansion efforts [17][18] - Sanmei Co., Ltd. is expected to benefit from ongoing demand in the refrigerant market, with projections for significant profit growth in the coming years [28]